Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19

Affiliations

• ¹ Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
• ² DBHi Bioinformatics Group, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
• ³ Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
• ⁴ Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
• ⁵ Laboratory of Genetics and Genomics, National Institute on Aging, NIH, Baltimore, MD, USA.
• ⁶ Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
• ⁷ Lonza Biologics, Portsmouth, NH, USA.
• ⁸ Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.
• ⁹ Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
• ¹⁰ Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA. andreit@pennmedicine.upenn.edu.
• ¹¹ Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA. andreit@pennmedicine.upenn.edu.
• ¹² Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA. andreit@pennmedicine.upenn.edu.